Bipolar Disorder Neuropsychopharmacology

REF: PD 35
Principle investigator:
Eduard Vieta
Contact details:



Research framework

The Bipolar Disorders Program provides clinical care, education and research on bipolar disorder. Our group has contributed to the late development, registration, and practical use of all the currently available drugs to treat Bipolar Disorder (BD).

The objectives of this research program:

  1. To foster neuropsychopharmacology research in the field of BD
  2. To improve clinical trial methodology and competitiveness in this arena

The most common techniques used are: Designing and implementing randomized controlled trials in BD. Randomization strategies. Stratification. Clinical trial methodology. Non inferiority designs. Adaptive designs. Observational studies.

The research group started working closely with pharmaceutical industry and quickly evolved into investigator-initiated studies and independent trials.

We are a multidisciplinary research group with expert psychiatrists, pharmacologists, pharmacists and nurses. Deep knowledge of the field and the methodological background.

The most relevant publications:

  • Vieta E et al. A randomized, double-blind, placebo-contrb olled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder.Eur Neuropsychopharmacol. 2012 Apr 11.
  • Kemp DE et al. Ziprasidone with adjunctive mood stabilizer in the maintenance treatment of bipolar I disorder: long-term changes in weight and metabolic profiles. Eur Neuropsychopharmacol. 2012;22(2):123-31.
  • Vieta E et al. Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol. 2011;14(8):1029-49.
  • Vieta E et al. Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study. Am J Psychiatry. 2008; 165(10):1316-25.
  • Vieta E, Cruz N. Head to head comparisons as an alternative to placebo-controlled trials. Eur Neuropsychopharmacol.  2011 Dec 26
  • Rosa AR et al. Six-month functional outcome of a bipolar disorder cohort in the context of a specialized-care program. Bipolar Disord. 2011;13(7-8):679-86.


Bipolar Disorder, Treatment, Neuropsychopharmacology

Main Challenges

Main challenges of this program are assessing the efficacy and safety of drugs in bipolar disorder in the era of personalized medicine through functional neuroimaging, neuropsychological tests, biomarkers, genetics and pharmacogenetics, and improving the methodology of clinical trials in bipolar disorder research.

The selected candidate will participate in the design, setting up and execution of projects, data analysis, paper writing as well as other research activities.

Candidates should have a MD degree, specialization in Psychiatry and PhD in Neuroscience, relevant publications in peer-reviewed journals.

Team strategic objective in IDIBAPS

The research activity of our group focuses on the neurobiology (genetics, biomarkers, neuropsychology, neuroimaging), epidemiology (clinical subtypes, comorbidity, psychometric assessment, functionality), and treatment of bipolar disorder (including pharmacological, biophysical, and psychosocial strategies). Team strategic objective is to study the causes and the mechanisms implicated in etiopathogenesis of Bipolar Disorder and investigate new treatments to ameliorate the prognosis of the disorder.

(Read eligibility criteria)